ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer Slates Biologics In China

by Michael McCoy
June 17, 2013 | APPEARED IN VOLUME 91, ISSUE 24

Boehringer Ingelheim has teamed up with China’s Zhangjiang Biotech & Pharmaceutical Base Development Co. for what it says will be the first plant for drugs based on mammalian cell cultures to be built in China by an international firm. In addition to being a drug company in its own right, Boehringer is a major contract manufacturer of biologic drugs. The German firm says the new plant, to cost more than $45 million, will provide development and clinical services to Chinese and multinational customers.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment